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Abstract
Recombinant T cell receptor ligands (RTLs) that target encephalitogenic T-cells can reverse clinical and histological signs of
EAE, and are currently in clinical trials for treatment of multiple sclerosis. To evaluate possible regulatory mechanisms, we
tested effects of RTL therapy on expression of pathogenic and effector T-cell maturation markers, CD226, T-bet and CD44,
by CD4+ Th1 cells early after treatment of MOG-35-55 peptide-induced EAE in C57BL/6 mice. We showed that 1–5 daily
injections of RTL551 (two-domain I-A
b covalently linked to MOG-35-55 peptide), but not the control RTL550 (‘‘empty’’ two-
domain I-A
b without a bound peptide) or Vehicle, reduced clinical signs of EAE, prevented trafficking of cells outside the
spleen, significantly reduced the frequency of CD226 and T-bet expressing CD4+ T-cells in blood and inhibited expansion of
CD44 expressing CD4+ T-cells in blood and spleen. Concomitantly, RTL551 selectively reduced CNS inflammatory lesions,
absolute numbers of CNS infiltrating T-bet expressing CD4+ T-cells and IL-17 and IFN-c secretion by CNS derived MOG-35-55
reactive cells cultured ex vivo. These novel results demonstrate that a major effect of RTL therapy is to attenuate Th1 specific
changes in CD4+ T-cells during EAE and prevent expansion of effector T-cells that mediate clinical signs and CNS
inflammation in EAE.
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Introduction
Recombinant T cell receptor ligands (RTLs) reverse clinical and
histological signs of EAE in an antigen-specific manner, and are
currently in clinical trials for treatment of multiple sclerosis [1,2,3].
Our earlier studies showed that treatment with single RTLs can
induce a cytokine switch in cognate T-cells that inhibits both target
and bystander T-cells [4]. Recently we have shown that RTLs
bind to surface receptors on B cells, macrophages and dendritic
cells, but not T-cells, through the MHC class II a1b1 moiety of the
RTL in an antigenic peptide-independent manner [5]. Antigen
specificity in RTL treatment of EAE strongly suggests potential
tolerogenic signals being delivered to T-cells following RTL
binding with APCs. In fact, our preliminary studies have
demonstrated that DR2-derived RTLs could induce changes in
cytokine secretion patterns without proliferation in human T-cell
clones [6]. Moreover, RTL201 (comprised of the rat RT1B MHC
moiety linked to Gp-MBP-72-89 peptide) could induce partial
activation of the cognate A1 T-cell hybridoma involving a CD3f
p23/p21 ratio shift, ZAP-70 phosphorylation, internal calcium
mobilization, NFAT activation, and transient IL-2 production [7].
However, the downstream effects of early signaling induced in T-
cells by RTLs that could potentially regulate clinical EAE and
cause its attenuation remain largely unknown. Considering the fact
that CD4 T-cells are initiators of EAE and are drivers of neuro-
immune degeneration in CNS [8], this study was designed with the
aim of obtaining mechanistic insights by exploring RTL551 (two-
domain I-A
b covalently linked to MOG-35-55 peptide) effects on
CD4+ T-cells in vivo after induction of clinical and histological
signs of EAE with MOG-35-55/CFA/Ptx in C57BL/6 mice.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21868Rapid resolution of EAE after RTL treatment prompted us to
study early time points after treatment initiation. Empty RTL550
(‘‘empty’’ two-domain I-A
b without a bound peptide) was used as
additional control to provide evidence that irrespective of similar
binding of empty RTLs to APCs, the nature of the bound peptide
is the determining factor for subsequent signal transduction in
immune cells. We showed that a single injection of RTL551, but
not the control RTL550, reduced clinical signs of EAE, prevented
trafficking of cells outside the spleen, significantly reduced the
frequency of CD226 and T-bet expressing CD4+ T-cells in blood
and inhibited expansion of CD44 expressing CD4+ T-cells in
blood and spleen. Concomitantly, RTL551 selectively reduced
absolute numbers of T-bet+CD4+ T-cells and IL-17 and IFN-c
secretion in the CNS. These novel results demonstrate that a
major effect of RTL therapy is to attenuate encephalitogenic
activity of Th1/Th17+ CD4+ T-cells during EAE and prevent
maturation of memory T-cells that mediate clinical signs and CNS
inflammation in EAE.
Materials and Methods
Animals
C57BL/6 male mice were obtained from Jackson Laboratories
(Bar Harbor, ME) at 7–8 wk of age. The mice were housed in the
Animal Resource Facility at the Portland Veterans Affairs Medical
Center (Portland, OR) in accordance with institutional guidelines.
The study was conducted in accordance with National Institutes of
Health guidelines for the use of experimental animals, and the
protocols were approved by the Institutional Animal Care and Use
Committee, protocol # 4508, local database ID # 2313.
Antigen
Mouse MOG-35-55 peptide (MEVGWYRSPFSRVVH-
LYRNGK) was synthesized from NeoMPS.
RTL construction, modification and production
General methods for the design, cloning and expression of
RTLs have been described previously [3,9]. In brief, a series of
murine MHC class II I-A
b-derived single chain beta-1/alpha-1
recombinant T-cell receptor ligands (‘‘RTLs’’), termed rI-A
b
(RTL550), were constructed by sequential site-directed mutagen-
esis of rI-A
q RTLs. The progenitor rI-A
q RTLs were constructed
using mRNA isolated from the splenocytes of DBA1/LacJ mice
using an Oligotex Direct mRNA mini kit (Qiagen, Inc., Valencia,
CA). cDNA of the antigen binding/TCR recognition domain of
murine I-A
q MHC class II b1 and a1 chains was derived from
mRNA using two pairs of PCR primers. The two chains were
sequentially linked by a 5 amino acid linker (GGQDD) in a two-
step PCR reaction with NcoI and XhoI restriction sites being
added to the amino terminus of the b1 chain and to the carboxyl
terminus of the a1 chain respectively, to create rI-A
q (RTL560).
‘‘Empty’’ rI-A
b (RTL550) was constructed by sequential site-
directed mutagenesis using ‘‘empty’’ rIA
q ((RTL560) as template.
The 22 site-directed mutations required were inserted using eight
primers containing the desired sequence changes and 4 consec-
utive mutagenesis cycles (QuikChange Multi site-directed muta-
genesis kit, Stratagene, Inc). Additional sequence encoding murine
MOG-35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) and a
flexible linker (GSGSGSGSGSGSGS) was added to the 59 end of
the b1 domain of rI-A
b RTL550 to form rI-A
b/MOG (RTL551).
The rI-A
b/MOG insert was ligated into pET21d(+) vector and
transformed into a Nova blue E. coli host (Novagen, Inc., Madison,
WI) for positive colony selection and sequence verification, and rI-
A
b/MOG plasmid constructs were then transformed into the
E. coli strain BL21(DE3) expression host (Novagen, Inc., Madison,
WI). Protein purification was as previously described [9,10] with a
30 to 40 mg yield of purified protein per liter of bacterial cell
culture.
Induction of active EAE and treatment with RTLs
C57BL/6 mice were inoculated in flanks with 0.2 ml of
emulsion containing 200 mg of MOG-35-55 peptide and an equal
volume of CFA containing 2 mg/ml of heat killed Mycobacterium
tuberculosis. Mice were also injected with 75 ng and 200 ng
pertussis toxin (Ptx) intraperitoneally on day 0 and 2 relative to
immunization. The mice were assessed for signs of EAE according
to the following scale: 0, normal; 1, limp tail or mild hind-limb
weakness; 2, moderate hind-limb weakness or mild ataxia; 3,
moderately severe hind-limb weakness; 4, severe hind-limb
weakness or mild fore-limb weakness or moderate ataxia; 5,
paraplegia with no more than moderate fore-limb weakness; and
6, paraplegia with severe fore-limb weakness or severe ataxia or
moribund condition. At the onset of clinical signs of EAE (days
12–14 when the clinical scores were$2), the mice were divided
into three groups and treated i.v. with 100 ml buffer as Vehicle-
control, 100 ml of 1 mg/ml RTL551 (containing MOG-35-55
peptide) or 100 ml of 1 mg/ml RTL550 (empty) daily for 5 days.
Mice were monitored for changes in disease score until they were
euthanized for ex vivo analyses.
Flow cytometry
Four-color (fluoresceinisothiocyanate, phycoerythrin, propi-
dium iodide, allophycocyanin) fluorescence flow cytometry
analyses were performed to determine the phenotypes of cells
following standard antibody staining procedures. At indicated time
points, cardiac blood was collected in EDTA followed by perfusion
of the mice with 1xPBS. For splenocytes, single cell suspensions of
spleens from vehicle, RTL550 and RTL551 treatment groups
were prepared by homogenizing the tissue through a fine mesh
screen. Blood cells were pelleted after lysis of red cells followed by
washing twice with RPMI. Mononuclear cells from the CNS were
isolated by Percoll gradient centrifugation as described [11]. Cells
from spleen, blood and CNS were resuspended in staining
medium (5% BSA, 1X PBS and 0.02% sodium azide) for FACS
staining. For intracellular cytokine determination, cells were
stimulated with leukocyte activation cocktail (BD PharMingen,
San Diego, CA ) for 6 hrs prior to surface staining. All antibodies
were purchased from BD PharMingen (San Diego, CA) or
eBioscience (San Diego, CA) unless otherwise indicated. Cells were
stained with the combination of following antibodies: CD4, CD8,
CD226, CD44. Intracellular staining of T-bet (Biolegend; San
Diego, CA), IL17 and IFNc (BD PharMingen, San Diego, CA)
was completed following overnight incubation in fixation/
permeabilization buffer (eBiosciences) and incubation with respec-
tive primary antibodies for 30 min. After staining, cells were
washed with staining medium and analyzed immediately with a
FACS Calibur using FCS express (Los Angeles, CA) software.
Data represent 20,000 live gated events. Absolute numbers of cells
were calculated from live-gated CNS cells.
Cytokine determination by multiplex luminex kit
Mononuclear cells from the CNS of individual mice were
cultured at 200,000 cells/well in a 96-well round-bottom culture
plate in stimulation medium (RPMI, 1% sodium pyruvate, 1% L-
glutamine, 0.4% 2-b-mercaptoethanol, 2% FBS) with 25 mg/ml
MOG-35-55 peptide for 48 h. Supernatants were then harvested
and stored at 280uC until testing for cytokines. Culture
supernatants were assessed for cytokine levels using a Luminex
RTL Inhibits Maturation of Pathogenic T Cells
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Richmond, CA) following manufacturer’s instructions. The
following cytokines were determined in a single assay in three
separate experiments: IFN-c, TNF-a, IL-2, IL-6, IL-13 and IL-17.
Histopathology
Intact spinal cords were removed from 4 mice in each group at
indicated time points of clinical disease and fixed in 10% Formalin
for 48 h. All the mice were perfused with PBS prior to organ
collection. The spinal cords were dissected after fixation and
embedded in paraffin before sectioning. The sections were stained
with H&E to assess inflammatory lesions, and analyzed by light
microscopy.
Statistical analysis
Statistical differences between disease scores of vehicle, RTL550
and RTL551 treatment groups were determined by Mann-
Whitney U test. Differences in percentages of cells expressing
various cell surface markers, splenocyte numbers and cytokine
responses were evaluated using Student’s t test. P values#0.05
were considered significant.
Results
Clinical EAE scores are significantly reduced in mice
treated with RTL551
Treatment of EAE mice with vehicle, RTL550 or RTL551 was
initiated at onset of clinical signs of disease followed by 4
additional daily injections. Clinical scores of EAE on the days of ex
vivo procedures are shown in Fig. 1. For all the results, Days (D)1,
3 and 6 post-onset indicates 1, 3 and 5 treatments respectively.
EAE progression was completely halted in the mice as early as one
RTL551 treatment and the RTL551 treated group had signifi-
cantly reduced clinical disease scores at all the time points as
compared to control groups (Vehicle and RTL550) of mice which
showed worsening disease scores over time (Fig. 1).
RTL551 prevents migration of cells from spleen of EAE
mice
At onset of clinical signs of EAE prior to treatment, there was a
significant 3X increase in the splenocyte numbers in mice
immunized with MOG-35-55/CFA/Ptx (cell number in naı ¨ve
vs. EAE mice, 45.5619.9 vs. 144.8654.4, Fig. 2). In the acute
phase of EAE, cells are still trafficking from the periphery into the
CNS, and as EAE progressed, there was a gradual decline in
splenocyte numbers in Vehicle and RTL550 treated mice (Fig. 2),
suggesting the migration of cells outside the spleen possibly
towards the CNS. Interestingly, RTL551-treated mice retained
the increased levels of cells in the spleen throughout the
observation period.
RTL551 treated mice had reduced frequency of
CD4+ T-cells in the blood at early time points
As compared to naı ¨ve mice, EAE mice had a significantly
increased percentage of CD4+ T-cells in the blood at onset of
clinical signs (naı ¨ve vs. onset, 7.762.0 vs. 14.962.9) and CD4+ T-
cell percentages remained significantly higher D1 post onset in
Vehicle (14.965.6) and RTL550 (15.562.0) treated mice
compared to RTL551 (8.865.9) treated mice (Fig. 3A & B).
During this initial phase of EAE, the increase in CD4+ T-cells in
the blood corresponds with increases of encephalitogenic CD4+ T-
cells in the CNS [12] and thus might indicate their migration from
spleen towards the CNS. Percentages of CD4+ T-cells in blood
decreased in all treatment groups on D3 post onset, followed by
increases in all groups on D6 post onset (Fig. 3B). Of importance,
the CD4+ T-cell percentages in the blood of RTL551 treated mice
remained significantly lower than Vehicle and RTL550 treated
mice at the D6 post onset time point (Fig. 3B).
Figure 1. EAE Mice treated with RTL551 at onset have
significantly reduced clinical scores as compared to vehicle
or RTL550 treated mice. Male C57BL/6 mice were immunized with
MOG-35-55/CFA/Ptx. Mice were scored for clinical signs of EAE as
outlined in Materials and Methods. Data presented are the mean6SD
disease scores of 8–10 mice per group. Significant differences between
the groups were determined using Mann Whitney U test.
doi:10.1371/journal.pone.0021868.g001
Figure 2. RTL551 prevents migration of cells outside spleen.
Splenocytes were counted from naı ¨ve mice and mice at indicated time
points after EAE induction. As compared to naı ¨ve mice, spleen cell
numbers increased after immunization and at onset of EAE followed by
gradual decline with EAE progression in control groups of mice,
possibly due to migration of cells outside the spleen towards the CNS.
This trafficking of cells outside the spleen is prevented after RTL551
treatment. Data presented are the mean6SD of 8 mice per group
except for naı ¨ve which had 5 mice. Significant differences between the
groups (p#0.05) were determined using Student’s t test and are
indicated by an asterisk.
doi:10.1371/journal.pone.0021868.g002
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CD226 and T-bet expressing CD4+ T-cells in the blood
during the early stages of EAE
CD226 and T-bet are two key Th1-associated markers that
have been linked to the encephalitogenic activity of CD4+ T-cells,
and it was thus of interest to evaluate the effects of RTL551 on
expression of these markers during treatment of mice with EAE.
Concomitant with the increase in CD4+ T-cells in the blood at
EAE onset, there were significantly elevated levels of CD226
(naı ¨ve vs. EAE onset, 1.660.7% vs. 4.160.1%) and T-bet (naı ¨ve
vs. EAE onset, 0.360.2% vs. 2.760.6%) in the CD4+ T-cells
(Fig. 4), thus illustrating the temporal association of these two Th1
markers with manifestation of EAE clinical signs. Of importance, a
single injection of RTL551 significantly reduced the percentages of
CD4+ CD226 (RTL551 D1 post onset, 2.461.1%, Fig. 4C) and
T-bet (RTL551 D1 post onset, 1.060.5%, Fig. 4D) expressing T-
cells in the blood compared to Vehicle or RTL550-treated mice.
While the control groups with EAE had consistently elevated levels
of CD226 and T-bet expressing CD4+ T-cells in the blood
throughout the observed time points (Fig. 4C & D, respectively),
mice treated with RTL551 had markedly reduced percentages of
these pathogenic CD4+ T-cells.
RTL551 prevents expansion of effector CD4+ T-cells in
the periphery
CD44 expressing CD4+ T-cells are increased in the spleen and
CNS of mice with EAE [13], and it was thus of interest to evaluate
effects of RTL551 treatment on this population of activated
effector cells during EAE (representative dot plots for CD44
staining on blood CD4+ T-cells on D3 post onset are shown in
Fig 5A). The percentage of CD4+ cells expressing CD44 was
significantly increased in EAE control mice vs. naı ¨ve mice on D3
post EAE onset both in blood (naı ¨ve vs. Vehicle & RTL550,
8.961.5% vs. 34.466.1% & 34.867.6%, respectively, Fig. 5B)
and spleen (naı ¨ve vs. Vehicle and RTL550, 20.665.4% vs.
36.267.5% & 33.864.5% respectively, Fig. 5C). Treatment of
EAE mice with RTL551 significantly reduced the percentages of
CD44 expressing CD4+ T-cells after 3 injections in the blood
(RTL551 D3 post onset, 21.264.3%; Fig. 5B) and spleen
(RTL551 D3 post onset, 24.764.4%, Fig. 5C). The concomitant
reduction of CD44 expressing CD4+ T-cells in blood and spleen of
RTL551 treated mice on D3 suggests that the reduced percentage
in blood was not due simply to sequestration of these cells in the
spleen, and might, rather, implicate the ability of RTL551 to
prevent the expansion of CD44 expressing CD4+ T-cells in the
Figure 3. Frequency of CD4+ T-cells is significantly reduced in the blood of mice treated with RTL551. Mice were euthanized at the
indicated time points after onset and isolated blood cells were lysed, stained with fluorescent antibodies and analyzed by flow cytometry.
Representative dot plot for CD4 staining in blood on D1 is shown in panel A. Sequential changes in CD4+ T-cell frequencies in the blood of mice with
EAE are shown in panel B. Data in panel B are mean6SD values from 8 mice per group except for naı ¨ve which had 5 mice. Significant differences
between the groups (p#0.05) were determined using Student’s t test and are indicated by an asterisk.
doi:10.1371/journal.pone.0021868.g003
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with EAE (not shown).
Reduction in IL-17 and IFN-c producing cells in the
spleen after RTL551 treatment
In order to study effector functions of the cells retained in the
spleen of RTL551 treated mice, intracellular staining for IL-17
and IFN-c was performed (Fig. 6). While D1 post onset spleens of
the three groups of mice had similar frequencies of IL-17 and IFN-
c producing cells (data not shown), significantly reduced
frequencies of IL-17 (D3 post onset, vehicle and RTL550 vs.
RTL551, 861.4 and 7.360.4; vehicle & RTL550 vs. RTL551,
p,0.05) and IFN-c (D3 post onset, vehicle and RTL550 vs.
RTL551, 1561.2 and 15.761 vs. 7.961.2; vehicle & RTL550 vs.
RTL551, p,0.05) producing CD4+ T cells were present in the
spleens of RTL551 treated mice (Fig. 6A & B). These observations
were also expanded to CD8+ T-cells to study whether inhibition of
Th1 CD4+ T cells in RTL551 treated mice influenced effector
functions of CD8+ T cells, too. Although we could not detect any
IL-17 secreting CD8+ T cells (data not shown), IFN-c producing
CD8 T cells were reduced in the splenocytes of RTL551 treated
mice on D3 post onset although the difference was not significant
(D3 post onset, vehicle and RTL550 vs. RTL551, 2362.8 and
2163 vs. 9.364.8; vehicle & RTL550 vs. RTL551, p=0.07,
Fig. 6C).
Rapid resolution of CNS inflammation in mice treated
with RTL551
Previously we reported a marked reduction of infiltrating cells
and a complete absence of inflammation in the CNS after
completing treatment of EAE with RTL551 [3]. Here we now
evaluate these factors in the CNS at early time points after
Figure 4. Treatment with RTL551 significantly reduces the percentages of CD226 and T-bet expressing CD4+ T-cells compared to
treatment with Vehicle or RTL550 in the blood of mice with EAE early after treatment initiation. Representative dot plots for CD226 and
T-bet staining, respectively, on CD4 T-cells in blood are shown in panels A & B. Sequential changes in the expression of CD226 and T-bet on CD4
T-cells in the blood of mice from the three groups during EAE are shown in panels C & D. Data in panels C & D are mean6SD values from 8 mice per
group except for naı ¨ve which had 5 mice. Significant differences between the groups (p#0.05) were determined using Student’s t test and are
indicated by an asterisk.
doi:10.1371/journal.pone.0021868.g004
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control groups of mice had the expected increases in CNS
inflammatory lesions, RTL551 treated mice had a striking
reduction in CNS inflammation even after a single treatment
(D1 post onset, Fig. 7A). Inflammation continued to resolve in
RTL551 treated mice (D3 post onset, Fig 7A) and as published
earlier, there was complete lack of inflammatory cells in the spinal
cords by D6 post onset (data not shown). Correspondingly, there
were significantly fewer inflammatory cells isolated from the CNS
of RTL551-treated mice during these early time points (Fig. 7B).
CNS analysis was limited to 3 days post onset due to complete
resolution of inflammation in the CNS of RTL treated mice by D6
post onset.
Selective reduction in recruitment of T-bet expressing
CD4+ T-cells into the CNS of mice treated with RTL551
Immuno-phenotyping of cells isolated from the CNS at
indicated time points after onset of EAE revealed that absolute
numbers of CD4+ T-cells recovered from the CNS increased with
time in the control groups (Fig. 8A & B). However, a single
RTL551 treatment resulted in reduced percentages as well as
significantly reduced absolute numbers (Fig. 8 A & B) of CD4+ T-
cells obtained from the CNS (absolute number of D1 vehicle &
RTL550 vs. RTL551, 34,90666,927 & 45,599614,318 vs.
16,023 vs. 7,845) and these differences were even more pro-
nounced on D3 (Fig. 8B). A similar pattern of RTL551 inhibition
of infiltrating CD8+ T-cells was also observed on D3 but not on
D1 post onset of EAE (Fig 8C). Of interest, the highest expression
of T-bet on CD4+ CNS T-cells was in the control groups at D1
post onset (vehicle & RTL550, 7.261.7% & 5.961.5%,
respectively; Fig. 8D &, E), a significant increase as compared to
onset (1.260.6%, p,0.001, Fig. 8E). However, the percentage
(3.461.7%, p,0.01, Fig 8E) and absolute number (Fig. 8F) of T-
bet expressing CD4+ T-cells recovered on D1 from the CNS of
RTL551 treated mice were significantly reduced vs. D1 controls,
but were not significantly increased vs. cells recovered at onset.
This result suggests that a single RTL551 injection limited the
number of infiltrating T-bet expressing CD4+ T-cells into the
CNS.
RTL551 induces early down-regulation of IL-17 and IFN-c
in the CNS
The rapid reduction of inflammatory infiltrates from CNS has
always been an intriguing feature of RTL mediated treatment of
EAE. An elegant recent study showed that cells expressing the
Th17+CD4+ phenotype (particularly) have the potential for
initiating immune mediated neuronal dysfunction in mice with
EAE [14]. This led us to evaluate the levels of IL-17 and IFN-c,
along with other cytokines, in the CNS during the early phases of
RTL551 treatment. During acute EAE, cells isolated from CNS
secreted high concentrations of IL-17, the highest levels detected
on D1 after onset (Fig. 9). Of paramount importance, reduction in
Figure 5. Treatment of EAE mice with RTL551 inhibits expansion of CD44 expressing CD4+ T-cells in the periphery compared to
treatment with Vehicle or RTL550. Splenocytes and lysed blood cells were stained with respective antibodies and subjected to flow cytometry.
Dot plot for CD44 staining on blood CD4+ T-cells on day 3 post onset is shown in panel A. Cells were gated on live CD4+ cells for this analysis. Values
in panels B & C are representative of 8 mice per group on D3 after onset of clinical signs of EAE except for naı ¨ve which had 5 mice. Significant
differences between the groups (p#0.05) were determined using Student’s t test and are indicated by brackets.
doi:10.1371/journal.pone.0021868.g005
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point (Fig. 8B) was associated with a significant reduction in IL-17
secretion in culture supernatants of MOG-35-55 peptide-stimu-
lated CNS cells (Fig. 9A). This was also associated with reduced
frequency of IL-17 producing cells in RTL551 treated CNS as
suggested by intracellular staining (Fig 9C). This is a key finding
that could be linked to RTL-mediated early intervention in the
EAE pathogenic process, causing disruption in the inflammatory
response and potentially sparing downstream neuronal damage
mediated by Th17 cells in the CNS. Considerable, albeit lower,
concentrations of IL-17 were still detected in the culture
supernatants of CNS cells isolated from D3 post EAE onset mice
from the control groups (Fig. 9), with continued inhibition by
RTL551 at this time point. Of added interest, the key Th1
cytokine, IFN-c, was also present in the MOG-35-55 activated
culture supernatants in control mice during early EAE (Fig. 9B &
D), and was also strongly inhibited in RTL551-treated mice. All
the other cytokines evaluated, including TNF-a, IL-2, IL-6 and
Figure 6. RTL551 treated mice had reduced frequencies of IL-17 and IFNc secreting cells in the spleen D3 post onset. Splenocytes
were stimulated with leukocyte activation cocktail and were stained with respective antibodies and subjected to flow cytometry. Representative dot
plots for IL-17 and IFN-c staining (respectively) on CD4+ T-cells are shown in panels A & B respectively. Cells were gated on CD4+ cells for this analysis.
IL-17 staining on gated CD8+ T-cells is shown in panel C. Data are representative of 3 mice per group.
doi:10.1371/journal.pone.0021868.g006
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peptide stimulated CNS cell culture supernatants and were not
different between RTL551 treated and control groups.
Discussion
Previous studies from our laboratory have established the
ability of RTL constructs to treat EAE in several different rat
and mouse models [2,3,4,15,16,17]. In all the models tested,
cognate RTL when used to treat EAE at onset induced rapid
remission from clinical EAE which is associated with resolution
of CNS inflammation. In this study, we explored the
mechanism and effect of RTLs specifically on encephalitogenic
CD4+ T-cells in the C57BL/6 model of EAE induced with
MOG-35-55/CFA/Ptx. Rapid resolution of EAE after
RTL551 treatment prompted us to explore immunologic
changes at early time points after EAE induction. We
established earlier that RTLs bind to antigen presenting cells
(APCs) through MHC class II a1b1 moiety and this is
independent of covalently bound peptide [5]. Several studies
from our group have shown that RTL treatment of EAE is very
antigen specific such that RTL551 will not inhibit EAE induced
with PLP-139-151 and RTL401 (containing PLP-139-151) is
ineffective in MOG-35-55 induced EAE [1,15]. These facts
strongly indicate towards undefined tolerogenic signals being
transmitted to CD4+ T-cells subsequent to RTL binding with
APCs. Moreover, unlike RTLs with covalently bound peptide,
empty RTL constructs have no effect on EAE progression [15],
suggesting that empty RTLs bound to APCs are unable to
deliver a complete set of tolerogenic signals to T cells.
Furthermore, we have shown in the past that equimolar
concentration (as cognate RTL) of encephalitogenic peptide
administered i.v. at EAE onset had no significant effect on the
progression of EAE [15].
The current study presents novel findings concerning cellular
effects of RTL551 on antigen experienced CD4+ T-cells. The
most important conclusions from this study are: 1) RTL551
treatment sequesters the encephalitogenic T-cells within the
spleen; 2) RTL551 selectively affects CD4+ T-cells and causes
reduction in CD226 and T-bet expressing CD4+ T-cells in the
blood early during EAE; 3) CD44 expressing CD4+ effector T-
cells are expanded in the periphery during EAE and RTL551
treatment prevents expansion of these effector T-cells; and 4) All
these peripheral events lead to reduced infiltration of T-bet
Figure 7. RTL551 treated mice have less infiltration of immune cells in the CNS. Panel A represents H&E staining on paraffin embedded
spinal cord sections from Vehicle, RTL550 or RTL551 treated C57BL/6 mice at indicated time points after EAE onset. Spinal cords from control groups
of mice (Panel A) showed dense mononuclear infiltration (arrows) and sections from RTL551 treated mice showed reduction in inflammatory cells.
Magnification: A, 5X; insets, 20X. Panel B is the mean6SD values of cells isolated from the CNS of mice from the three groups (8 mice per group) at
indicated time points. Significant differences between the groups (p#0.05) were determined using Student’s t test and are indicated by an asterisk.
doi:10.1371/journal.pone.0021868.g007
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CNS. This study provides significant insights into the early and
sequential changes influencing encephalitogenicity of CD4+ T-
cells during EAE and the fate of encephalitogenic CD4+ T-cells
after RTL551 administration at EAE disease onset.
Mice were evaluated at early time points after onset of clinical
signs of EAE and treatment with vehicle, ‘‘empty’’ RTL550 or
RTL551 containing MOG peptide to follow the fate of
encephalitogenic MOG-35-55 peptide-reactive CD4+ T-cells. At
onset of EAE, there was three-fold increase in spleen cell numbers
Figure 8. Selective reduction of T-bet expressing CD4 T-cells from the CNS of EAE mice treated with RTL551. T-bet expressing CD4+
T-cells were increased in the CNS of control groups of mice with EAE when compared to onset. One injection of RTL551 induced significant reduction
and recruitment of CD4+ T-cells into the CNS. Representative dot plots for CD4+ and T-bet staining on the cells isolated from CNS of mice are shown
in panels A & D. Sequential changes in mean6SD absolute numbers of CD4+ and CD8+ cells in the CNS of control and RTL551 treated mice are
shown in panels B & C. Percentages are demonstrated in panel E and panel F shows absolute numbers of T-bet expressing CD4+ T-cells in the CNS of
mice D1 post onset. There were 8 mice per group and significant differences between the groups (p#0.05) were determined using Student’s t test
and are indicated by an asterisk (panels C and D) or by brackets (panels E and F).
doi:10.1371/journal.pone.0021868.g008
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naive mice (Fig. 2). Furthermore, spleen cell numbers steadily
decreased with the progression of EAE in control groups of mice,
suggesting their migration out of the spleen towards the CNS.
However RTL551 treated mice maintained increased spleen cell
numbers at all the time points tested. Considering that spleen cell
numbers were higher in RTL551 treated mice at D1, D3 and D6
post onset and that the percentages of major cellular subtypes in
the spleen were not different at any of the time points between
groups, it is apparent that absolute numbers of each of these
cellular subtypes were higher in the spleen of RTL551 treated
mice. Therefore, further evidence for any specific cellular subtype
affected by RTL551 treatment was sought in the blood of EAE
mice treated at onset with vehicle, RTL550 or RTL551. We found
a significant increase (as compared to naı ¨ve mice) in CD4+ T-cells
in the blood of control groups of mice at onset and on D1 after
onset (Fig. 3). During this early post-priming time point in EAE,
cells are making their way into the CNS, particularly CD4+ T-cells
which are the major initiators of EAE [8]. A significant decrease in
the frequency of CD4+ T-cells in the blood after one RTL551
injection provides evidence for a major crucial intervention in
EAE pathogenesis caused by RTL551. We strongly believe that
Figure 9. IL-17 and IFN-c were significantly reduced in the culture supernatants of cells isolated from the CNS of RTL551 treated
mice as compared to control groups of mice (panel A & B). Cytokine production was quantified in the supernatants from mononuclear cells
isolated from CNS of mice at indicated time points and stimulated with MOG-35-55 peptide in vitro. Supernatants were harvested after 48h of culture
and assayed for cytokine production using a Bio-Plex assay kit. Data are presented as the mean6SD of three replicate cultures from pooled cells, and
are representative of 4 individual mice. Significant differences between the groups (p#0.05) were determined using Student’s t test and are indicated
by an asterisk. RTL551 treated mice had reduced frequency of IL-17 and IFN-c producing CD4 T-cells in the CNS (Fig 9 C & D).
doi:10.1371/journal.pone.0021868.g009
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blood because: 1) RTL551 injections given to naı ¨ve mice had no
effect on CD4+ T-cells in any organ including blood (data not
shown); and 2) empty RTL550 had no effect on the frequencies of
CD4+ T-cells in the blood of EAE mice (Fig. 2). We observed
interesting kinetics for expression of two key Th1 cell markers,
CD226 and T-bet, on CD4+ T-cells in the blood of control groups
of mice (Fig. 4). Recently, CD226 has been shown to be present
selectively on differentiated Th1 cells and while it is constitutively
expressed by CD8+ T-cells, CD226 is upregulated on CD4+ T-
cells upon activation [18,19,20]. Nonsynonymous single nucleo-
tide polymorphism rs763361/Gly307Ser in exon 7 of CD226 has
been associated with multiple autoimmune diseases including
T1D, MS and possibly AITD and RA [19]. In T-cells CD226 is
functional only upon activation and it physically associates with
LFA-1 upon antigen recognition by the T cell receptor [21]. This
association facilitates Fyn protein tyrosine kinase mediated
phosphorylation of Tyr
322 of CD226 [21] and this might play
an important role for Th1 polarization from naı ¨ve T cells since
Th2 clones express low level of Fyn protein in mice and CD4+
naı ¨ve T-cells from Fyn-deficient mice polarize towards Th2 cells
even in the absence of IL-4 and IL-13 [22,23]. A more recent
study has implicated CD226 as a signal transducer of LFA-1
following T cell activation [24]. Administration of CD226
monoclonal antibody inhibited expansion of PLP-139-151 specific
CD4+ T-cells and delayed the onset as well as severity of EAE
[18]. In addition, Shibuya et al. showed that a dominant negative
mutation in the CD226 signaling domain in naı ¨ve human CD4+
T-cells strongly suppressed Th1 differentiation, suggesting that
CD226 signaling is critical for Th1 differentiation [24]. Our
findings provide evidence that CD226 is indeed up-regulated early
on CD4+ T-cells, and we for the first time report the kinetics of
CD226 expression on CD4+ T-cells in the blood of mice with
EAE.
Another well-known and very important Th1 cell surface
molecule, T-bet, is a transcription factor that was first associated
with the differentiation of Th1 cells and IFN-c production by
CD4+ T cells [25]. Based on its ability to induce a pro-
inflammatory immune response, T-bet has been found to regulate
factors, including but not limited to STAT-1 expression and IL-
23R transcription, which have been linked to pathogenicity in
EAE and MS. T-bet is essential for the development of EAE, as T-
bet deficient mice are resistant to EAE induction [26,27,28].
Myelin-specific T cells from T-bet-deficient mice fail to transfer
disease to wild-type mice [27,28], confirming that T-bet is
necessary for the generation of encephalitogenic T cells.
Moreover, up-regulation of T-bet expression has been reported
during exacerbations in the peripheral blood CD4+ T-cells of
RRMS patients compared to patients in remission and healthy
controls [29].
Our results show that CD4+ T-cells in blood do significantly
upregulate CD226 and T-bet expression in mice at EAE onset
when compared to naı ¨ve mice that had very low detectable levels
of CD226 and T-bet (Fig. 4). Furthermore, CD226 and T-bet
expressing CD4+ T-cells remained elevated in the blood of control
groups, but were significantly reduced after RTL551 treatment,
thus indicating early RTL-mediated inhibition of CD4-T cells
expressing these key pathogenic Th1 markers.
In EAE, D3 post onset was marked by a significant increase in
CD44 expressing CD4+ T-cell in the blood and spleen of control
groups of mice (Fig. 5). Increases in effector CD4+ T-cells were
detectable as early as EAE onset, although the difference only
became significant on D3 post onset. CD44 is up-regulated on
naı ¨ve T cells after TCR mediated activation and its high
expression is maintained on antigen experienced CD4+ T-cells
[30]. While control groups of mice exhibited substantial
percentages of CD4+ effector T-cells by D3, RTL551 treatment
inhibited the maintenance of CD4+ effector T-cells in the
periphery This was also associated with decrease in IL-17 and
IFN-c secreting cells in the spleen (Fig 6). Taken together, these
results suggest that RTL551 treatment strongly reduced the Th1
immune response in the periphery early during EAE. No effects of
empty RTL550 on Th1 and CD44 cell markers on CD4+ T-cells
were noted, thus implicating MOG-35-55 peptide dependent
effects of RTL551 on MOG-35-55 primed CD4+ T-cells. This
result supports our earlier observations that cognate T-cell
specificity is indispensable for successful RTL treatment effects [4].
We have previously reported that RTL treatment dramatically
reduces CNS infiltration in mice when treatment is started at onset
of EAE [3,16]. In the current study, CNS tissue of mice with EAE
was examined at early time points after RTL551 treatment in
order to identify events initiated in the CNS that lead to
subsequent resolution of inflammation (Fig. 7). Our results
demonstrated rapid and progressive reductions in lesions and
CNS inflammatory cell numbers during the treatment phase of
EAE with RTL551, with significant changes observed as early as 1
day after a single injection of RTL551.
Two additional very dramatic and rapid changes induced in the
CNS by a single RTL551 injection were: 1) selective reduction in
absolute numbers of total and T-bet expressing CD4+ T-cells; and
2) significant down-regulation in IL-17 and IFN-c secretion by
MOG-35-55 reactive cells isolated from the CNS of RTL551
treated mice compared to control groups of mice. D1 post onset is
a very active early phase of EAE, with CD4+ T-cells playing a
crucial role as initiators of the disease. Indeed, at this time point
the CNS cells from the control groups of mice had the greatest
frequency of T-bet expressing CD4+ T-cells (Fig. 8) and secreted
high levels of IL-17 and IFN-c when cultured ex vivo with MOG
peptide (Fig. 9A & B). Recent data have raised the possibility that
T-bet’s role in T cell differentiation is not limited to Th1 cells and
therefore, lack of T-bet expressing CD4+ T-cells in the CNS of
mice treated with RTL551 might attribute to the reduction of both
IL-17 and IFN-c. In support of this assertion, it has been shown
that generation of autoreactive Th17 cells in the absence of T-bet
is not sufficient to induce autoimmunity, even when Th17 cells are
differentiated in vivo [26,31]. Moreover, administration of T-bet
siRNA to mice immunized with myelin peptides in CFA reduces
both IFN-c and IL-17 production [32]. Abrogation of IL-17
production in the CNS early during EAE could have important
implications for reducing subsequent disease progression, best
explained by a recent study that used a combination of
microscopic techniques to discern the process of immune cell
mediated neuronal damage [14]. This study emphasized that
during EAE, the presence of CD4+ T-cells is the most relevant
feature for immune mediated neuronal dysfunction and that CNS-
specific Th17 cells play a dominant role compared to Th1 cells in
initiation of neuronal injury [14]. Absence or reduction of IL-17
secreting cells in the CNS during early phases of EAE in RTL551
treated mice would abolish or mitigate the neurotoxic effects of
this inflammatory cascade in the CNS and downstream recruit-
ment of other inflammatory cells. While it is clear from our data
that one RTL551 injection prevents the recruitment of additional
CD4+ T-cells into the CNS, the mechanisms that limit infiltration
of inflammatory cells remain an open question.
We thus hypothesize that RTL treatment of EAE is a two step
process where binding of the truncated form of MHC Class II to
mononuclear cells (MNC), including monocyte subpopulations, plays
a critical role in initiating a tolerogenic response in CD4+ T-cells
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result in the reduction of encephalitogenic CD4+ T-cells expressing
T-bet and CD226 and secreting IL-17. In support of this proposed
mechanism, we have shown previously that RTLs bind to antigen
presenting cells in a peptide independent manner [5]. Furthermore,
our recent data demonstrates that cell-bound RTL can be detected
within the lumbar region of the spinal column for at least two days
after completion of treatment of mice with EAE, suggesting potential
interactions between RTL-bound APCs and encephalitogenic CD4+
T-cells not only in the periphery but also in the CNS. Future studies
will be performed to confirm whether the reduction in CD4+ T-cells
observed in blood and CNS is due to deletion of antigen primed
CD4+ T-cells or their re-routing to other lymphoid organs besides
spleen.
These novel results demonstrate that a major effect of RTL
therapy is to attenuate Th1 specific changes in CD4+ T-cells
during EAE and prevent expansion of both Th1 and Th17 effector
T-cells that mediate clinical signs and CNS inflammation in EAE.
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